Soluble TNF and IL-2 receptors in patients with breast cancer
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články
PubMed
11208388
PII: 1320
Knihovny.cz E-zdroje
- MeSH
- CD antigeny krev MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory prsu krev patologie terapie MeSH
- receptory interleukinu-2 krev MeSH
- receptory TNF - typ I MeSH
- receptory TNF - typ II MeSH
- receptory TNF krev MeSH
- rozpustnost MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- studie případů a kontrol MeSH
- TNF-alfa metabolismus MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- CD antigeny MeSH
- nádorové biomarkery MeSH
- receptory interleukinu-2 MeSH
- receptory TNF - typ I MeSH
- receptory TNF - typ II MeSH
- receptory TNF MeSH
- TNF-alfa MeSH
INTRODUCTION: Cytokines were shown both to enhance tumour growth and formation of metastases and to inhibit proliferation of tumour cells. TNF alpha may mediate apoptosis and necrosis of cancer cells, while the exact role of IL-2 remains to be elucidated. Plasma levels of TNF alpha and TNF and IL-2 soluble receptors (sTNF-R, sIL-2R) should thus be in some relation to some biological characteristics of the breast cancer. MATERIAL AND METHODS: Plasma levels of TNF alpha, sTNF-R I and II and sIL-2R were measured in 31 women with different stages of breast cancer both before the institution of therapy and after 3 months of the treatment. RESULTS: Plasma levels of both types of sTNF-Rs were higher in patients with breast cancer than in controls (sTNF-R I--2166.6 +/- 568.9 vs. 1121.3 +/- 260.6 pg/ml, p < 0.001, sTNF-R II--3792.8 +/- 958.9 vs. 1996.2 +/- 404.3 pg/ml, p < 0.001) with no significant difference between clinical stages. Plasma levels of both sTNF-R (0.871, p < 0.001) and sIL-2R tightly correlated with each other. Plasma levels of TNF alpha decreased after treatment (from 3.92 +/- 1.86 to 3.40 +/- 1.15 pg/ml, p < 0.01), but plasma levels of sTNF-Rs and sIL-2R were not influenced by the therapy. CONCLUSION: Plasma levels of soluble TNF receptors may thus serve as a non-specific marker of the untreated breast cancer. Their relation to other biologic characteristics of this tumour is not clear. It remains also to be clarified if the long-term treatment leads to the normalization of sTNF-Rs plasma levels.